Crossmark

Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii

Crossref DOI link: https://doi.org/10.1186/s13756-019-0502-x

Published Online: 2019-03-06

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Niu, Tianshui

Luo, Qixia

Li, Yaqing

Zhou, Yanzi

Yu, Wei

Xiao, Yonghong
Funding

Funding for this research was provided by:

the key research and development program of Zhejiang province (2015C03032)

The national key research and development program of China (No. 2017YFC1200203)
License Information

Text and Data Mining valid from 2019-03-06
More Information

Article History

Received: 6 December 2018

Accepted: 27 February 2019

First Online: 6 March 2019

Ethics approval and consent to participate

: Ethics approval for this study was submitted and approved through Research Ethics.Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University.(Reference Number 2017–699).

: Not applicable.

: The authors declare that they have no competing interests

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.